vs
Fortrea Holdings Inc.（FTRE）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Fortrea Holdings Inc.的季度营收约是Guardant Health, Inc.的2.3倍（$660.5M vs $281.3M）。Fortrea Holdings Inc.净利率更高（-4.9% vs -45.7%，领先40.8%）。Guardant Health, Inc.同比增速更快（39.4% vs -5.2%）。Fortrea Holdings Inc.自由现金流更多（$121.6M vs $-54.2M）。过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs -0.1%）
Fortrea Holdings Inc.是一家总部位于美国北卡罗来纳州达勒姆、注册地为特拉华州的合同研究组织，业务覆盖90个国家，主要服务制药、生物技术和医疗器械行业客户，为相关领域的研发提供专业支持。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
FTRE vs GH — 直观对比
营收规模更大
FTRE
是对方的2.3倍
$281.3M
营收增速更快
GH
高出44.6%
-5.2%
净利率更高
FTRE
高出40.8%
-45.7%
自由现金流更多
FTRE
多$175.8M
$-54.2M
两年增速更快
GH
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $660.5M | $281.3M |
| 净利润 | $-32.5M | $-128.5M |
| 毛利率 | — | 64.6% |
| 营业利润率 | -2.1% | -43.0% |
| 净利率 | -4.9% | -45.7% |
| 营收同比 | -5.2% | 39.4% |
| 净利润同比 | 46.9% | -15.8% |
| 每股收益（稀释后） | $-0.25 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTREGH
| Q4 25 | $660.5M | $281.3M | ||
| Q3 25 | $701.3M | $265.2M | ||
| Q2 25 | $710.3M | $232.1M | ||
| Q1 25 | $651.3M | $203.5M | ||
| Q4 24 | $697.0M | $201.8M | ||
| Q3 24 | $674.9M | $191.5M | ||
| Q2 24 | $662.4M | $177.2M | ||
| Q1 24 | $662.1M | $168.5M |
净利润FTREGH
| Q4 25 | $-32.5M | $-128.5M | ||
| Q3 25 | $-15.9M | $-92.7M | ||
| Q2 25 | $-374.9M | $-99.9M | ||
| Q1 25 | $-562.9M | $-95.2M | ||
| Q4 24 | $-61.2M | $-111.0M | ||
| Q3 24 | $-27.9M | $-107.8M | ||
| Q2 24 | $-138.4M | $-102.6M | ||
| Q1 24 | $-101.0M | $-115.0M |
毛利率FTREGH
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
营业利润率FTREGH
| Q4 25 | -2.1% | -43.0% | ||
| Q3 25 | -1.2% | -37.3% | ||
| Q2 25 | -46.5% | -45.9% | ||
| Q1 25 | -79.9% | -54.6% | ||
| Q4 24 | -8.0% | -62.4% | ||
| Q3 24 | -2.7% | -61.3% | ||
| Q2 24 | -7.7% | -56.8% | ||
| Q1 24 | -5.6% | -59.2% |
净利率FTREGH
| Q4 25 | -4.9% | -45.7% | ||
| Q3 25 | -2.3% | -35.0% | ||
| Q2 25 | -52.8% | -43.0% | ||
| Q1 25 | -86.4% | -46.8% | ||
| Q4 24 | -8.8% | -55.0% | ||
| Q3 24 | -4.1% | -56.3% | ||
| Q2 24 | -20.9% | -57.9% | ||
| Q1 24 | -15.3% | -68.2% |
每股收益（稀释后）FTREGH
| Q4 25 | $-0.25 | $-1.01 | ||
| Q3 25 | $-0.17 | $-0.74 | ||
| Q2 25 | $-4.14 | $-0.80 | ||
| Q1 25 | $-6.25 | $-0.77 | ||
| Q4 24 | $-0.68 | $-0.90 | ||
| Q3 24 | $-0.31 | $-0.88 | ||
| Q2 24 | $-1.55 | $-0.84 | ||
| Q1 24 | $-1.13 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $174.6M | $378.2M |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $563.5M | $-99.3M |
| 总资产 | $2.7B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FTREGH
| Q4 25 | $174.6M | $378.2M | ||
| Q3 25 | $131.3M | $580.0M | ||
| Q2 25 | $81.2M | $629.1M | ||
| Q1 25 | $101.6M | $698.6M | ||
| Q4 24 | $118.5M | $525.5M | ||
| Q3 24 | $105.3M | $585.0M | ||
| Q2 24 | $126.2M | $933.7M | ||
| Q1 24 | $92.8M | $1.0B |
总债务FTREGH
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FTREGH
| Q4 25 | $563.5M | $-99.3M | ||
| Q3 25 | $580.8M | $-354.5M | ||
| Q2 25 | $589.2M | $-305.5M | ||
| Q1 25 | $858.8M | $-250.8M | ||
| Q4 24 | $1.4B | $-139.6M | ||
| Q3 24 | $1.5B | $-60.1M | ||
| Q2 24 | $1.5B | $-1.6M | ||
| Q1 24 | $1.6B | $68.3M |
总资产FTREGH
| Q4 25 | $2.7B | $2.0B | ||
| Q3 25 | $2.7B | $1.3B | ||
| Q2 25 | $2.8B | $1.3B | ||
| Q1 25 | $3.1B | $1.3B | ||
| Q4 24 | $3.6B | $1.5B | ||
| Q3 24 | $3.7B | $1.5B | ||
| Q2 24 | $3.6B | $1.6B | ||
| Q1 24 | $4.2B | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $129.1M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $121.6M | $-54.2M |
| 自由现金流率自由现金流/营收 | 18.4% | -19.3% |
| 资本支出强度资本支出/营收 | 1.1% | 9.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $88.3M | $-233.1M |
8季度趋势，按日历期对齐
经营现金流FTREGH
| Q4 25 | $129.1M | $-26.4M | ||
| Q3 25 | $86.8M | $-35.4M | ||
| Q2 25 | $21.8M | $-60.3M | ||
| Q1 25 | $-124.2M | $-62.7M | ||
| Q4 24 | $17.1M | $-64.5M | ||
| Q3 24 | $-2.4M | $-51.1M | ||
| Q2 24 | $273.7M | $-94.0M | ||
| Q1 24 | $-25.6M | $-30.3M |
自由现金流FTREGH
| Q4 25 | $121.6M | $-54.2M | ||
| Q3 25 | $79.5M | $-45.8M | ||
| Q2 25 | $14.3M | $-65.9M | ||
| Q1 25 | $-127.1M | $-67.1M | ||
| Q4 24 | $13.9M | $-83.4M | ||
| Q3 24 | $-10.6M | $-55.3M | ||
| Q2 24 | $262.5M | $-99.1M | ||
| Q1 24 | $-34.9M | $-37.2M |
自由现金流率FTREGH
| Q4 25 | 18.4% | -19.3% | ||
| Q3 25 | 11.3% | -17.3% | ||
| Q2 25 | 2.0% | -28.4% | ||
| Q1 25 | -19.5% | -33.0% | ||
| Q4 24 | 2.0% | -41.3% | ||
| Q3 24 | -1.6% | -28.9% | ||
| Q2 24 | 39.6% | -55.9% | ||
| Q1 24 | -5.3% | -22.1% |
资本支出强度FTREGH
| Q4 25 | 1.1% | 9.9% | ||
| Q3 25 | 1.0% | 3.9% | ||
| Q2 25 | 1.1% | 2.4% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 0.5% | 9.4% | ||
| Q3 24 | 1.2% | 2.2% | ||
| Q2 24 | 1.7% | 2.9% | ||
| Q1 24 | 1.4% | 4.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTRE
暂无分部数据
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
